Precigen is trading at $4.46, up 5.57%; broader biotech strength and risk-on trading are the most plausible context for the November 6 move, with no new company-specific catalyst surfaced. - The XBI was up 2.01%; Moderna’s earnings beat and raised outlook lifted sector sentiment. - The rebound follows a sharp recent slide. Precigen reported strong Q3 revenue and positive cash flow ahead of guidance, but those results were reported before November 6.